Most participants (61%) showed high levels of adherence to DKD guidelines, but they presented a substantial gap in knowledge regarding the optimum screening time of DKD in patients with type 1 diabetes, the ideal screening test for albuminuria, the recommended interval for the routine surveillance, the annual screening tests, the therapeutic target of hemoglobin A1c (HbA1c), the indications of Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) and the timing of referral to a nephrologist. Here, SLC5A2 is linked to type 1 diabetes mellitus.